The stock of Apellis Pharmaceuticals Inc (APLS) has gone down by -1.83% for the week, with a -17.32% drop in the past month and a -27.11% drop in the past quarter. The volatility ratio for the week is 3.74%, and the volatility levels for the past 30 days are 4.25% for APLS. The simple moving average for the last 20 days is -4.50% for APLS’s stock, with a simple moving average of -42.46% for the last 200 days.
Is It Worth Investing in Apellis Pharmaceuticals Inc (NASDAQ: APLS) Right Now?
The 36-month beta value for APLS is at 0.86. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for APLS is 100.98M, and currently, shorts hold a 15.11% of that float. The average trading volume for APLS on October 22, 2024 was 2.02M shares.
APLS) stock’s latest price update
Apellis Pharmaceuticals Inc (NASDAQ: APLS) has experienced a decline in its stock price by -4.00 compared to its previous closing price of 28.00. However, the company has seen a fall of -1.83% in its stock price over the last five trading days. benzinga.com reported 2024-10-16 that William Blair has initiated coverage on Apellis Pharmaceuticals, Inc. APLS and notes that Apellis was the first company to successfully target complement C3, which has led to the approval of two therapies: Empaveli (systemic pegcetacoplan) for paroxysmal nocturnal hemoglobinuria and Syfovre (intravitreal pegcetacoplan) for geographic atrophy secondary to age-related macular degeneration.
Analysts’ Opinion of APLS
Piper Sandler gave a rating of “Neutral” to APLS, setting the target price at $46 in the report published on May 31st of the current year.
APLS Trading at -20.74% from the 50-Day Moving Average
After a stumble in the market that brought APLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.58% of loss for the given period.
Volatility was left at 4.25%, however, over the last 30 days, the volatility rate increased by 3.74%, as shares sank -17.85% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -27.37% lower at present.
During the last 5 trading sessions, APLS fell by -1.83%, which changed the moving average for the period of 200-days by -55.74% in comparison to the 20-day moving average, which settled at $28.15. In addition, Apellis Pharmaceuticals Inc saw -55.10% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at APLS starting from Dunlop A. Sinclair, who sale 37,000 shares at the price of $36.23 back on Sep 16 ’24. After this action, Dunlop A. Sinclair now owns 100,000 shares of Apellis Pharmaceuticals Inc, valued at $1,340,597 using the latest closing price.
Chopas James George, the VP/Chief Accounting Officer of Apellis Pharmaceuticals Inc, sale 192 shares at $36.21 during a trade that took place back on Sep 16 ’24, which means that Chopas James George is holding 38,141 shares at $6,952 based on the most recent closing price.
Stock Fundamentals for APLS
Current profitability levels for the company are sitting at:
- -0.53 for the present operating margin
- 0.86 for the gross margin
The net margin for Apellis Pharmaceuticals Inc stands at -0.54. The total capital return value is set at -0.44. Equity return is now at value -109.19, with -36.58 for asset returns.
Based on Apellis Pharmaceuticals Inc (APLS), the company’s capital structure generated 0.64 points at debt to capital in total, while cash flow to debt ratio is standing at -0.88. The debt to equity ratio resting at 1.75. The interest coverage ratio of the stock is -19.76.
Currently, EBITDA for the company is -515.42 million with net debt to EBITDA at -0.35. When we switch over and look at the enterprise to sales, we see a ratio of 5.48. The receivables turnover for the company is 2.0for trailing twelve months and the total asset turnover is 0.68. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.08.
Conclusion
In conclusion, Apellis Pharmaceuticals Inc (APLS) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
